trial summary · NCT07757802
Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults
A Clinical Trial to Evaluate the Safety and Immunogenicity of ACU-026-001-1-Adjuvanted CH505 Protein Nanoparticles (DV901-NP) Alone or Boosted With CH505 NP (DV902-NP) or CH505 mRNAs in Adults in Overall Good Health Without HIV
Trial record from the TrialBase DB dataset, status RECRUITING, condition HIV, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This Phase 1 study will evaluate the safety, tolerability, and immune responses of investigational CH505 HIV vaccine regimens in adults in overall good health without HIV. Participants will receive CH505 protein nanoparticle vaccines (DV901-NP) formulated with the investigational adjuvant ACU-026-001-1, followed by either CH505 protein nanoparticle (DV902-NP) or CH505 mRNA vaccine boosters. The study will assess the ability of these regimens to induce HIV-specific immune responses, including B-cell responses associated with the development of broadly neutralizing antibodies. An immunology cohort will also evaluate how the location of booster vaccination affects immune responses.
Source record: https://clinicaltrials.gov/study/NCT07757802
Facts
| registry id | NCT07757802 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | HIV |
| sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| sponsor class | NIH |
| enrollment | 54 |
| start date | 2026-12-01 |
| primary completion | 2028-06-07 |
| completion | 2028-10-07 |
| results posted | not reported |
Conditions
- HIV
Interventions
- DV901-NP
- DV902-NP
- CH505 TF mRNA-gp160
- CH505 w24 mRNA-gp160
- ACU-026-001-1
Countries
- United States
Intervention types: BIOLOGICAL
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.